utable to pharmacokinetic phenomena. These are usually due to alterations in hepatic drug metabolic pathways catalyzed by the cytochrome P450 (CYP) system. The adverse effects can result from inhibition or induction of such metabolic enzymes; the inhibition appears to be more important in many poisoning cases.
Introduction
The majority of serious cases of drug-drug interactions of toxicological and clinical interest appear to be attrib-1 3
(triazolam [8] , fl unitrazepam [9] , and alprazolam [10] ). Fatal poisoning involving coadministration of alcohol and benzodiazepines, especially these three drugs, continues to be a serious social problem.
In this study we investigated the in vitro interaction between ethanol and imipramine by monitoring and its three main metabolites [desipramine, 2-hydroxyimipramine (2-OHI), and 2-hydroxydesipramine (2-OHD)] at high-dose concentrations using human liver microsomes.
Materials and methods

Materials
NADPH was purchased from Oriental Yeast (Tokyo, Japan). Clomipramine (internal standard, IS) and ethanol were purchased from Sigma (St. Louis, MO, USA) and Wako (Osaka, Japan), respectively. Imipramine and its three metabolites (desipramine, 2-OHI, and 2-OHD) were kindly provided by Mitsubishi Pharma (Osaka, Japan). All other chemicals and reagents used were of the highest quality commercially available. Microsomes from three pooled human livers (catalog nos: H003, H013 and H032) containing representative activities of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 were obtained from Daiichi Pure Chemical (Tokyo, Japan).
Enzyme assay
The incubation mixture contained enzyme protein (0.125 mg), 0.1 M potassium phosphate buffer (pH 7.4), 0.1 mM NADPH, imipramine (substrate concentration 0-10 µM; therapeutic level 0.155-0.465 µM, toxic level 3.27 µM, fatal level 4.74-6.33 µM) [5] and ethanol (0-80 mM; toxic level 20-40 mM, fatal level 70-80 mM) in a total volume of 0.5 ml. Incubations were initiated following a 3-min preincubation at 37°C by the addition of NADPH and were generally carried out for 20 min in a shaking water bath at 37°C. The reaction was terminated by adding 100 µl of acetonitrile and 3 ml of t-butyl methyl ether containing 9.5 µg/ml clomipramine (IS). After vortex mixing for 5 min, the tubes were centrifuged at 1200 g for 3 min. The organic phase was transferred to a clean conical tube and evaporated in a water bath at about 40°C under a gentle stream of nitrogen. The residue was dissolved in 200 µl of mobile phase and 50 µl was injected into the high-performance liquid chromatography (HPLC) system.
Determination of imipramine metabolites
The HPLC equipment consisted of a pump (Model CCPS, Tosho, Tokyo, Japan) and a variable-wavelength ultraviolet (UV) detector (Model UV-8020, Tosho). Separation was achieved using a C 18 reversed-phase column (150 mm × 4.6 mm i.d., particle size 3 µm, Inertsil ODS-3, GL Sciences, Tokyo, Japan). The mobile phase was 50 mM K 2 HPO 4 /methanol/acetonitrile (50 : 10 : 40, v/v/v) and the fl ow rate was 0.7 ml/min. The absorbance of the eluent was monitored at 254 nm. All instruments were operated at ambient laboratory temperature (ca. 23°C). The retention times of 2-OHD, 2-OHI, desipramine, and IS in a spiked sample of human liver microsomes were 3.2, 3.8, 6.3, and 16.2 min, respectively. The limits of detection (LOD) of desipramine, 2-OHI, and 2-OHD were 20, 25, and 10 nM, respectively. The intraand interassay coeffi cients of variation (CV) for the three metabolites were less than 5%.
Statistical analysis
To determine signifi cant differences between group mean values, data were subjected to a one-way analysis of variance (ANOVA) test for repeated measures. Differences were considered signifi cant at P < 0.05. Results are expressed as means ± standard error. Table 1 shows in vitro production rates for imipramine metabolites desipramine, 2-OHI, and 2-OHD according to various concentrations of ethanol and imipramine. Only the production of 2-OHD, the main metabolite of imipramine, was signifi cantly inhibited by 15%-50% by ethanol, but that of desipramine and 2-OHI was not. This inhibition was not dependent on the ethanol concentrations tested.
Results and discussion
Koyama et al. [1] reported that the metabolism of imipramine was most effi ciently catalyzed by CYP2D6, followed by CYP1A2 and CYP2C19 in a recombinant human CYP isoform study. However, it is not known which isozyme(s) is responsible for the interaction between imipramine and ethanol at the present time.
Some reports of in vitro experiments on the interaction between ethanol and drugs through CYP isozymes should be mentioned. Rubin et al. [11] reported that ethanol (10, 50, and 100 mM) in vitro inhibited the activities of aniline (competitive) and pentobarbital (mixed type) hydroxylases, and the demethylation of aminopyrene (competitive) and ethylmorphine (mixed type). Schuppel and Kuthe [12] also studied the in vitro inhibition by ethanol of microsomal hydroxylation for a series of barbiturates (amobarbital, cyclobarbital, and pentobarbital: mixed type), but hexobarbital hydroxylation remained unaffected by ethanol (210 mM). In contrast, Cinti et al. [13] reported that using liver slices, N-demethylation of aminopyrine was stimulated by 35%-40% at a low ethanol concentration (2 mM), whereas no stimulation occurred at a high concentration (100 mM).
In conclusion, our results using a human liver microsomal preparation showed that the formation of the 2-OHD metabolite of imipramine is inhibited by ethanol. To our knowledge, this kind of study has not been reported. It is possible that enhanced toxicity may be attained by simultaneous administration of high-dose ethanol and imipramine in a human body.
In the near future, the specifi c CYP isozyme(s), which is responsible for interaction between ethanol and imipramine, should be identifi ed; such a study will be useful for assessing the enhanced toxicity when both compounds are ingested simultaneously in forensic and clinical toxicology. 
